Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Current Investments (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Cash & Current Investments data on record, last reported at $29.4 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 7.15% year-over-year to $29.4 million; the TTM value through Sep 2025 reached $29.4 million, up 7.15%, while the annual FY2024 figure was $34.8 million, 21.84% down from the prior year.
  • Cash & Current Investments reached $29.4 million in Q3 2025 per PLX's latest filing, down from $33.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $76.9 million in Q2 2021 and bottomed at $20.8 million in Q3 2022.
  • Average Cash & Current Investments over 5 years is $40.0 million, with a median of $34.8 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: surged 119.89% in 2021, then crashed 62.86% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $39.0 million in 2021, then crashed by 43.11% to $22.2 million in 2022, then surged by 100.9% to $44.6 million in 2023, then dropped by 21.84% to $34.8 million in 2024, then dropped by 15.68% to $29.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $29.4 million in Q3 2025, $33.4 million in Q2 2025, and $34.7 million in Q1 2025.